Replies to post #718712 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Yes, it will happen. You can count on it.

Since you mentioned about SAB, it reminds me of the SAB members on Amgen. The interesting part is that Antoni Ribas is a SAB member and his former research associate Dr. Siwen Hu-Lieskovan is also a SAB member. I found it is unusual. I suspect BP would try to avoid something that can be labeled as nepotism.
https://www.amgen.com/about/leadership
https://www.amgen.com/about/leadership/scientific-advisory-boards/siwen-hu-lieskovan
https://profiles.ucla.edu/antoni.ribas#toc-id0

I just found out that Amgen has a target therapy drug approved by FDA in 2019 and it is called PCSK9 inhibitor which I found overexpressed in three brain tumor types too. Can you imagine what would happen if NWBO's technology could help Amgen find more targets for heart diseases?

Sometimes genetic insights lead to the development of a new target or new therapy in a remarkably short time frame, as was the case with Amgen’s development of Repatha® (evolocumab), the first PCSK9i inhibitor approved to reduce cardiovascular events like heart attack and stroke in patients with cardiovascular disease, and monoclonal antibodies that have now been used to treat more than 1 million patients.2,3 Through its work with deCODE, about 65% of Amgen’s non-oncology portfolio has been genetically validated to various degrees.4

https://www.amgen.com/stories/2022/04/5-things-amgen-is-doing-to-help-bend-the-curve-in-cardiovascular-disease